Evidence map›Paper›PMID 35920939›Full record

ArticleArchives of osteoporosis2022

Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada.

T Oliveira, J Brown, A G Juby, P Schneider, R J Wani, M Packalen, S Avcil, S Li, M Farris, E Graves and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of osteoporosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

T OliveiraAmgen Canada Inc, Mississauga, ON, Canada.
J BrownDepartment of Medicine, Division of Rheumatology, Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada.ORCID http://orcid.org/0000-0003-1910-788X
A G JubyDepartment of Medicine, Division of Geriatric Medicine, University of Alberta, Edmonton, AB, Canada.
P SchneiderDivision of Orthopaedic Trauma, Department of Surgery, University of Calgary, Calgary, AB, Canada.
R J WaniAmgen Canada Inc, Mississauga, ON, Canada.ORCID http://orcid.org/0000-0002-2422-7758
M PackalenAmgen Canada Inc, Mississauga, ON, Canada.
S AvcilAmgen Canada Inc, Mississauga, ON, Canada.
S LiMedlior Health Outcomes Research Ltd, Calgary, AB, Canada.
M FarrisMedlior Health Outcomes Research Ltd, Calgary, AB, Canada.
E GravesMedlior Health Outcomes Research Ltd, Calgary, AB, Canada.
S McMullenMedlior Health Outcomes Research Ltd, Calgary, AB, Canada. Suzanne.mcmullen@medlior.com.ORCID http://orcid.org/0000-0001-7852-9930
D L KendlerDepartment of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada.
Amgen (Canada) · CAHealth Economics and Outcomes Research (United Kingdom) · GBUniversité Laval · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE/

introductionThe objective of this study was to describe osteoporosis-related care patterns during the coronavirus disease 2019 (COVID-19) pandemic in Alberta, Canada, relative to the 3-year preceding.

methodsA repeated cross-sectional study design encompassing 3-month periods of continuous administrative health data between March 15, 2017, and September 14, 2020, described osteoporosis-related healthcare resource utilization (HCRU) and treatment patterns. Outcomes included patients with osteoporosis-related healthcare encounters, physician visits, diagnostic and laboratory test volumes, and treatment initiations and disruptions. The percent change between outcomes was calculated, averaged across the control periods (2017-2019), relative to the COVID-19 periods (2020).

resultsRelative to the average control March to June period, all HCRU declined during the corresponding COVID-19 period. There was a reduction of 14% in patients with osteoporosis healthcare encounters, 13% in general practitioner visits, 9% in specialist practitioner visits, 47% in bone mineral density tests, and 13% in vitamin D tests. Treatment initiations declined 43%, 26%, and 35% for oral bisphosphonates, intravenous bisphosphonates, and denosumab, respectively. Slight increases were observed in the proportion of patients with treatment disruptions. In the subsequent June to September period, HCRU either returned to or surpassed pre-pandemic levels, when including telehealth visits accounting for 33-45% of healthcare encounters during the COVID periods. Oral bisphosphonate treatment initiations remained lower than pre-pandemic levels.

conclusionsThis study demonstrates the COVID-19 pandemic and corresponding public health lockdowns further heightened the "crisis" around the known gap in osteoporosis care and altered the provision of care (e.g., use of telehealth and initiation of treatment). Osteoporosis has a known substantial care and management disparity, which has been classified as a crisis. The COVID-19 pandemic created additional burden on osteoporosis patient care with healthcare encounters, physician visits, diagnostic and laboratory tests, and treatment initiations all declining during the initial pandemic period, relative to previous years.

Indexed as

COVID-19OsteoporosisAlbertaCommunicable Disease ControlCross-Sectional StudiesDiphosphonatesHumansPandemicsDiphosphonatesCare patternsCOVID-19Healthcare resource utilizationOsteoporosisPandemic

Identifiers

PMID35920939
PMCPMC9349101
OpenAlexW4289545046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.